drugset / Trial / NCT05198752
A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.
Timeline
- Start
- 2022-03-18
- Primary completion
- 2023-12-22
- Completion
- 2024-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SW1115C3 | Messenger RNA (mRNA) | 50 ug | Subcutaneous |
| Subject | SW1115C3 | Messenger RNA (mRNA) | 100 ug | Subcutaneous |
| Subject | SW1115C3 | Messenger RNA (mRNA) | 150 ug | Subcutaneous |